Single oral doses of (±) 3,4-methylenedioxymethamphetamine ('Ecstasy') produce lasting serotonergic deficits in non-human primates: Relationship to plasma drug and metabolite concentrations

International Journal of Neuropsychopharmacology

Volumn 16, Issue 4, 2013, Pages 791-801

  Mueller, Melanie ^a   Yuan, Jie ^a   McCann, Una D ^a   Hatzidimitriou, George ^a   Ricaurte, George A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Amphetamines; drug abuse; MDMA; neurotoxicity; pharmacokinetics; serotonin

Indexed keywords

3,4 DIHYDROXYMETHAMPHETAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 HYDROXY 3 METHOXYMETHAMPHETAMINE; DRUG METABOLITE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BRAIN REGION; CLINICAL ASSESSMENT; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; LIMIT OF DETECTION; NERVOUS SYSTEM INJURY; NEUROCHEMISTRY; NEUROTOXICITY; NONHUMAN; PRIMATE; PRIORITY JOURNAL; PUTAMEN; SEROTONINERGIC SYSTEM; SQUIRREL MONKEY; THALAMUS;

ADMINISTRATION, ORAL; ANIMALS; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PRIMATES; SAIMIRI; SEROTONIN; SEROTONIN AGENTS;

EID: 84875749411     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145712000582     Document Type: Article

References (48)

1. Battaglia G, Yeh SY, O'Hearn E, Molliver ME, et al. (1987). 3, 4-Methylenedioxymethamphetamine and 3, 4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. Journal of Pharmacology and Experimental Therapeutics 3, 911-916.
2. Baumann MH, Zolkowska D, Kim I, Scheidweiler KB, et al. (2009). Effects of dose and route of administration on pharmacokinetics of (+ or-)-3, 4-methylenedioxymethamphetamine in the rat. Drug Metabolism and Disposition 11, 2163-2170.
3. Callahan BT, Cord BJ, Ricaurte GA (2001). Long-term impairment of anterograde axonal transport along fiber projections originating in the rostral raphe nuclei after treatment with fenfluramine or methylenedioxymethamphetamine. Synapse 2, 113-121.
4. Cami J, Farre M, Mas M, Roset PN, et al. (2000). Human pharmacology of 3, 4-methylenedioxymethamphetamine ('ecstasy'): psychomotor performance and subjective effects. Journal of Clinical Psychopharmacology 4, 455-466.
5. Chu T, Kumagai Y, DiStefano EW, Cho AK (1996). Disposition of methylenedioxymethamphetamine and three metabolites in the brains of different rat strains and their possible roles in acute serotonin depletion. Biochemical Pharmacology 6, 789-796.
6. de la Torre R, Farre M (2004). Neurotoxicity of MDMA (ecstasy): the limitations of scaling from animals to humans. Trends in Pharmacological Sciences 10, 505-508.
7. de la Torre R, Farre M, Ortuno J, Mas M, et al. (2000). Non-linear pharmacokinetics of MDMA ('ecstasy') in humans. British Journal of Clinical Pharmacology 2, 104-109.
8. Freedman RR, Johanson CE, Tancer ME (2005). Thermoregulatory effects of 3, 4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology 2, 248-256.
9. Gergen JA, McLean PD (1962). A Stereotaxic Atlas of the Squirrel Monkey's Brain (Saimiri sciureus). Public Health Service Publication No. 933. US Washington, DC: Department of Health, Education, and Welfare.
10. Green AR, King MV, Shortall SE, Fone KC (2011). Lost in translation: preclinical studies on MDMA provide information on mechanisms of action, but do not allow accurate prediction of adverse events in humans. British Journal of Pharmacology. Published online: 20 December 2011. doi:10.1111/j.1476-5381.2011. 01819.x.
11. Green AR, Mechan AO, Elliott JM, O'Shea E, et al. (2003). The pharmacology and clinical pharmacology of 3, 4-methylenedioxymethamphetamine (MDMA, 'ecstasy'). Pharmacological Reviews 3, 463-508.
12. Grob CS, Poland RE, Chang L, Ernst T (1996). Psychobiologic effects of 3, 4-methylenedioxymethamphetamine in humans: methodological considerations and preliminary observations. Behavioural Brain Research 1-2, 103-107.
13. Helmlin HJ, Bracher K, Bourquin D, Vonlanthen D, et al. (1996). Analysis of 3, 4-methylenedioxymethamphetamine (MDMA) and its metabolites in plasma and urine by HPLC-DAD and GC-MS. Journal of Analytical Toxicology 6, 432-440.
14. Irvine RJ, Keane M, Felgate P, McCann UD, et al. (2006). Plasma drug concentrations and physiological measures in 'dance party' participants. Neuropsychopharmacology 31, 424-430.
15. Kish SJ, Lerch J, Furukawa Y, Tong J, et al. (2010). Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography/[(11)C]DASB and structural brain imaging study. Brain 133, 1779-1797.
16. Kolbrich EA, Goodwin RS, Gorelick DA, Hayes RJ, et al. (2008). Plasma pharmacokinetics of 3, 4-methylenedioxymethamphetamine after controlled oral administration to young adults. Therapeutic Drug Monitoring 3, 320-332.
17. Laruelle M, Baldwin RM, Malison RT, Zea-Ponce Y, et al. (1993). SPECT imaging of dopamine and serotonin transporters with [123I]beta-CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse 4, 295-309.
18. Liechti ME, Gamma A, Vollenweider FX (2001). Gender differences in the subjective effects of MDMA. Psychopharmacology 2, 161-168.
19. McCann UD, Ricaurte GA (2001). Caveat emptor: editors beware. Neuropsychopharmacology 3, 333-336.
20. McCann UD, Ridenour A, Shaham Y, Ricaurte GA (1994). Serotonin neurotoxicity after (+/-)3, 4-methylenedioxymethamphetamine (MDMA; 'Ecstasy'): a controlled study in humans. Neuropsychopharmacology 2, 129-138.
21. McCann UD, Szabo Z, Scheffel U, Dannals RF, et al. (1998). Positron emission tomographic evidence of toxic effect of MDMA ('Ecstasy') on brain serotonin neurons in human beings. Lancet 9138, 1433-1437.
22. Mechan A, Yuan J, Hatzidimitriou G, Irvine RJ, et al. (2006). Pharmacokinetic profile of single and repeated oral doses of MDMA in squirrel monkeys: relationship to lasting effects on brain serotonin neurons. Neuropsychopharmacology 31, 339-350.
23. Meyer MR, Maurer HH (2010). Metabolism of designer drugs of abuse: an updated review. Current Drug Metabolism 5, 468-482.
24. Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, et al. (2011). The safety and efficacy of {+/-}3, 4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. Journal of Psychopharmacology 4, 439-452.
25. Molliver ME, Berger UV, Mamounas LA, Molliver DC, et al. (1990). Neurotoxicity of MDMA and related compounds: anatomic studies. Annals of the New York Academy of Sciences 600, 649-661; discussion 661-664.
26. Mordenti J and Chappell W (1989). The use of interspecies scaling in toxicokinetics. In: Yacobi A, Kelly J, Batra V (Eds.), Toxicokinetics in New Drug Development (pp. 42-96). New York: Pergamon Press.
27. Morefield KM, Keane M, Felgate P, White JM, et al. (2011). Pill content, dose and resulting plasma concentrations of 3, 4-methylendioxymethamphetamine (MDMA) in recreational 'ecstasy' users. Addiction 106, 1293-1300.
28. Mueller M, Kolbrich EA, Peters FT, Maurer HH, et al. (2009a). Direct comparison of (+/-) 3, 4-methylenedioxymethamphetamine ('ecstasy') disposition and metabolism in squirrel monkeys and humans. Therapeutic Drug Monitoring 3, 367-373.
29. Mueller M, Kolbrich-Spargo EA, Peters FT, Huestis MA, et al. (2009b). Hydrolysis of 3, 4-methylenedioxymethamphetamine (MDMA) metabolite conjugates in human, squirrel monkey, and rat plasma. Analytical and Bioanalytical Chemistry 393, 1607-1617.
30. Mueller M, Peters FT, Huestis MA, Ricaurte GA, et al. (2009c). Simultaneous liquid chromatographic-electrospray ionization mass spectrometric quantification of 3, 4-methylenedioxymethamphetamine (MDMA, Ecstasy) and its metabolites 3, 4-dihydroxymethamphetamine, 4-hydroxy-3-methoxymethamphetamine and 3, 4-methylenedioxyamphetamine in squirrel monkey and human plasma after acidic conjugate cleavage. Forensic Science International 1-3, 64-68.
31. Mueller M, Peters FT, Maurer HH, McCann UD, et al. (2008). Nonlinear pharmacokinetics of (+/-)3, 4-methylenedioxymethamphetamine (MDMA, 'Ecstasy') and its major metabolites in squirrel monkeys at plasma concentrations of MDMA that develop after typical psychoactive doses. Journal of Pharmacology and Experimental Therapeutics 1, 38-44.
32. Mueller M, Yuan J, Felim A, Neudorffer A, et al. (2009). Further studies on the role of metabolites in (+/-)-3, 4-methylenedioxymethamphetamine-induced serotonergic neurotoxicity. Drug Metabolism and Disposition 10, 2079-2086.
33. O'Hearn E, Battaglia G, De Souza EB, Kuhar MJ, et al. (1988). Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. Journal of Neuroscience 8, 2788-2803.
34. Peters FT, Samyn N, Wahl M, Kraemer T, et al. (2003). Concentrations and ratios of amphetamine, methamphetamine, MDA, MDMA, and MDEA enantiomers determined in plasma samples from clinical toxicology and driving under the influence of drugs cases by GC-NICI-MS. Journal of Analytical Toxicology 8, 552-559.
35. Reneman L, Booij J, Majoie CB, Van Den Brink W, et al. (2001). Investigating the potential neurotoxicity of Ecstasy (MDMA): an imaging approach. Human Psychopharmacology 8, 579-588.
36. Ricaurte G, Bryan G, Strauss L, Seiden L, et al. (1985). Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals. Science 4717, 986-988.
37. Ricaurte GA, DeLanney LE, Irwin I, Langston JW (1988a). Toxic effects of MDMA on central serotonergic neurons in the primate: importance of route and frequency of drug administration. Brain Research 1, 165-168.
38. Ricaurte GA, DeLanney LE, Wiener SG, Irwin I, et al. (1988b). 5-Hydroxyindoleacetic acid in cerebrospinal fluid reflects serotonergic damage induced by 3, 4-methylenedioxymethamphetamine in CNS of non-human primates. Brain Research 2, 359-363.
39. Ricaurte GA, Martello AL, Katz JL, Martello MB (1992). Lasting effects of (+/-)-3, 4-methylenedioxymethamphetamine (MDMA) on central serotonergic neurons in nonhuman primates: neurochemical observations. Journal of Pharmacology and Experimental Therapeutics 2, 616-622.
40. Sarkar S, Schmued L (2010). Neurotoxicity of ecstasy (MDMA): an overview. Current Pharmaceutical Biotechnology 5, 460-469.
41. Scheidweiler KB, Ladenheim B, Barnes AJ, Cadet JL, et al. (2011). (+/-)-3, 4-Methylenedioxymethamphetamine and metabolite disposition in plasma and striatum of wild-type and multidrug resistance protein 1a knock-out mice. Journal of Analytical Toxicology 7, 470-480.
42. Schmidt CJ (1987). Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. Journal of Pharmacology and Experimental Therapeutics 1, 1-7.
43. Steele TD, McCann UD, Ricaurte GA (1994). 3, 4- Methylenedioxymethamphetamine (MDMA, 'Ecstasy'): pharmacology and toxicology in animals and humans. Addiction 5, 539-551.
44. Szabo Z, McCann UD, Wilson AA, Scheffel U, et al. (2002). Comparison of (+)-(11)C-McN5652 and (11)C-DASB as serotonin transporter radioligands under various experimental conditions. Journal of Nuclear Medicine 5, 678-692.
45. Tancer ME, Johanson CE (2001). The subjective effects of MDMA and mCPP in moderate MDMA users. Drug and Alcohol Dependence 1, 97-101.
46. Vollenweider FX, Gamma A, Liechti M, Huber T (1998). Psychological and cardiovascular effects and short-term sequelae of MDMA ('ecstasy') in MDMA-naive healthy volunteers. Neuropsychopharmacology 4, 241-251.
47. Vollenweider FX, Jones RT, Baggott MJ (2001). Caveat emptor: editors beware. Neuropsychopharmacology 4, 461-463.
48. Yang J, Jamei M, Heydari A, Yeo KR, et al. (2006). Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA. Journal of Psychopharmacology 20, 842-849.